Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma

NCT07744750 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma
Richter Transformation
CLL / SLL
MZL

Interventions

DRUG: Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma

Sponsor

Changzhou No.2 People's Hospital